JP7755597B2 - 細胞 - Google Patents

細胞

Info

Publication number
JP7755597B2
JP7755597B2 JP2022561019A JP2022561019A JP7755597B2 JP 7755597 B2 JP7755597 B2 JP 7755597B2 JP 2022561019 A JP2022561019 A JP 2022561019A JP 2022561019 A JP2022561019 A JP 2022561019A JP 7755597 B2 JP7755597 B2 JP 7755597B2
Authority
JP
Japan
Prior art keywords
cells
fas
cell
nucleic acid
fasl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022561019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023521330A5 (https=
JP2023521330A (ja
JPWO2021205176A5 (https=
Inventor
カラム マッケンジー
ショーン コルドバ
マーティン プーレ
Original Assignee
オートラス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2005331.0A external-priority patent/GB202005331D0/en
Priority claimed from GBGB2017358.9A external-priority patent/GB202017358D0/en
Application filed by オートラス リミテッド filed Critical オートラス リミテッド
Publication of JP2023521330A publication Critical patent/JP2023521330A/ja
Publication of JP2023521330A5 publication Critical patent/JP2023521330A5/ja
Publication of JPWO2021205176A5 publication Critical patent/JPWO2021205176A5/ja
Priority to JP2025138496A priority Critical patent/JP2025170345A/ja
Application granted granted Critical
Publication of JP7755597B2 publication Critical patent/JP7755597B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022561019A 2020-04-09 2021-04-08 細胞 Active JP7755597B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025138496A JP2025170345A (ja) 2020-04-09 2025-08-21 細胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2005331.0 2020-04-09
GBGB2005331.0A GB202005331D0 (en) 2020-04-09 2020-04-09 Cell
GBGB2017358.9A GB202017358D0 (en) 2020-11-02 2020-11-02 Cell
GB2017358.9 2020-11-02
PCT/GB2021/050866 WO2021205176A2 (en) 2020-04-09 2021-04-08 Cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025138496A Division JP2025170345A (ja) 2020-04-09 2025-08-21 細胞

Publications (4)

Publication Number Publication Date
JP2023521330A JP2023521330A (ja) 2023-05-24
JP2023521330A5 JP2023521330A5 (https=) 2024-02-09
JPWO2021205176A5 JPWO2021205176A5 (https=) 2024-02-09
JP7755597B2 true JP7755597B2 (ja) 2025-10-16

Family

ID=75539696

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022561019A Active JP7755597B2 (ja) 2020-04-09 2021-04-08 細胞
JP2025138496A Pending JP2025170345A (ja) 2020-04-09 2025-08-21 細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025138496A Pending JP2025170345A (ja) 2020-04-09 2025-08-21 細胞

Country Status (7)

Country Link
US (1) US20230113183A1 (https=)
EP (1) EP4132963A2 (https=)
JP (2) JP7755597B2 (https=)
CN (1) CN115315439A (https=)
AU (1) AU2021253759A1 (https=)
CA (1) CA3174812A1 (https=)
WO (1) WO2021205176A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201720949D0 (en) 2017-12-15 2018-01-31 Autolus Ltd Cell
JP2024541501A (ja) * 2021-11-25 2024-11-08 ドイチェス クレブスフォルシュンクスツェントルム スチフトゥング デス エッフェントリヒェン レヒツ Ｃｄ９５ポリペプチド

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508219A (ja) 2015-03-05 2018-03-29 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052906B1 (en) 1999-04-16 2006-05-30 Celltech R & D Limited Synthetic transmembrane components
IL145918A0 (en) * 2001-10-14 2002-07-25 Ares Trading Sa Method and kit for monitoring recruitment of proteins to the intracellular domain of a receptor in intact cells
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
CA2999037A1 (en) * 2015-09-23 2017-03-30 Cytoimmune Therapeutics, LLC Flt3 directed car cells for immunotherapy
GB201716728D0 (en) * 2017-10-12 2017-11-29 Autolus Ltd Cell
GB201720949D0 (en) * 2017-12-15 2018-01-31 Autolus Ltd Cell
EP3810753A1 (en) * 2018-06-19 2021-04-28 Autolus Limited Cell
CA3114788A1 (en) * 2018-09-28 2020-04-02 Memorial Sloan-Kettering Cancer Center Immunoresponsive cells expressing dominant negative fas and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508219A (ja) 2015-03-05 2018-03-29 フレッド ハッチンソン キャンサー リサーチ センター 免疫調節性融合タンパク質およびその使用
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Also Published As

Publication number Publication date
EP4132963A2 (en) 2023-02-15
JP2023521330A (ja) 2023-05-24
CA3174812A1 (en) 2021-10-14
AU2021253759A1 (en) 2022-09-01
JP2025170345A (ja) 2025-11-18
WO2021205176A2 (en) 2021-10-14
US20230113183A1 (en) 2023-04-13
CN115315439A (zh) 2022-11-08
WO2021205176A3 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
US12187769B2 (en) Cell
AU2016272457B2 (en) Cell
AU2016342560B2 (en) Receptor
AU2016303355B2 (en) Therapeutic agents
EP3724320B1 (en) Cell
CN107922951B (zh) 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体
JP2025170345A (ja) 細胞
US20230348560A1 (en) Chimeric ilt receptor compositions and methods
WO2022029431A1 (en) Chimeric receptor binding tgf-beta
JP6842688B2 (ja) キメラ抗原受容体
CA3251133A1 (en) Artificial immune receptors
JP7054181B2 (ja) キメラ抗原受容体
KR20260052956A (ko) TGFβ 스위치 수용체, 이를 코딩하는 핵산, 이를 포함하는 세포 및 약학 조성물
CA2993746C (en) Therapeutic agents
CN119613529A (zh) Egfr多肽及其应用
EP4076506A1 (en) Cell
NZ737662B2 (en) Cell

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251003

R150 Certificate of patent or registration of utility model

Ref document number: 7755597

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150